American Journal of Preventive Cardiology (Sep 2024)

Real-world impact of transitioning from one lipoprotein(a) assay to another in a clinical setting

  • Janeni Jeevanathan,
  • Sigrid M. Blom,
  • Thomas Olsen,
  • Kirsten B. Holven,
  • Erik K. Arnesen,
  • Torleif Trydal,
  • Børge G. Nordestgaard,
  • Michael Sovershaev,
  • Ying Chen,
  • Kjetil Retterstøl,
  • Jacob J. Christensen

Journal volume & issue
Vol. 19
p. 100726

Abstract

Read online

Background and aims: Different lipoprotein(a) [Lp(a)] assays may affect risk stratification of individuals and thus clinical decision-making. We aimed to investigate how transitioning between Lp(a) assays at a large central laboratory affected the proportion of individuals with Lp(a) result above clinical thresholds. Methods: We studied nationwide clinical laboratory data including 185,493 unique individuals (47.7 % women) aged 18-50 years with 272,463 Lp(a) measurements using Roche (2000-2009) and Siemens Lp(a) assay (2009-2019). Results: While the majority of individuals (66-75 %) had low levels of Lp(a) (50 mg/dL, 40 % more individuals with Lp(a) >100 mg/dL and 80 % more individuals with Lp(a) > 180 mg/dL than the currently used Siemens assay, likely due to calibration differences. Conclusion: Transitioning from one Lp(a) immunoassay to another had significant impact on Lp(a) results, particularly in individuals approaching clinically relevant Lp(a) thresholds.

Keywords